Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2022 15:07 ET | Source: Syntekabio

Syntekabio (KOSDAQ:226330.KQ) Presents Neoantigen Prediction Technology at Cancer Immunotherapy Conference CICON22

New York, N.Y., United States, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ:226330.KQ), a global AI drug discovery and development company, will present its neoantigen prediction technology...
September 07, 2022 05:45 ET | Source: POSCO International Corporation

POSCO International Corporation Files Early Warning Report in Respect of Its Interest in NorthWest Copper Corp.

SEOUL, South Korea, Sept. 07, 2022 (GLOBE NEWSWIRE) -- POSCO International Corporation (“POSCO”) announces that it has acquired 7,228,916 common shares (the “Tranche 3 Shares”) of NorthWest Copper...
February 14, 2022 21:46 ET | Source: SeAH Steel Holdings

Lee Joo-sung Named President & CEO of SeAH Steel Holdings

SEOUL, South Korea, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Korean steel conglomerate SeAH Group (KRX: 003030.KS), one of the largest Korean steel pipe manufacturer, is proud to announce Lee Joo-sung as...
February 07, 2022 08:30 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference

SUWON, Republic of Korea, Feb. 07, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
January 03, 2022 08:30 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences

SUWON, Republic of Korea., Jan. 03, 2022 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
November 30, 2021 08:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board with Appointment of Nucleic Acid Therapeutics and Immunology Specialist Dr. Gunther Hartmann

SUWON, Republic of Korea, Nov. 30, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the appointment of Dr. Gunther...
October 21, 2021 12:00 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference

SUWON, Republic of Korea, Oct. 21, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
October 20, 2021 08:30 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A

SUWON, Republic of Korea, Oct. 20, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has selected...
October 12, 2021 07:00 ET | Source: OliX Pharmaceuticals; Hansoh Pharmaceutical Group Co, Ltd

Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China

Companies to focus on cardiovascular, metabolic, and other indicationsOliX will receive initial upfront payment of $6.5 million with up to $450 million plus royalties SHANGHAI, China and SUWON,...
September 24, 2021 08:30 ET | Source: OliX Pharmaceuticals

OliX Pharmaceuticals to Present at 2021 Oligonucleotide Therapeutics Society Virtual Conference

SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company will present new...